☆ 4.5 Letter

A Response to: Letter to the Editor Regarding Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

ADVANCES IN THERAPY (2022)

Get Full Text
Add to Collection

Journal

ADVANCES IN THERAPY
Volume 39, Issue 8, Pages 3862-3865

Publisher

SPRINGER
DOI: 10.1007/s12325-022-02214-1

Keywords

Benralizumab; Biologic; Severe asthma; Clinical remission

Categories

Medicine, Research & Experimental Pharmacology & Pharmacy

Funding

  1. Dan Jackson, Ph.D., CMPP (CiTRUS Health Group)
  2. AstraZeneca (Cambridge, UK)

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.